Eight FDA-class homeopathic drug products. One creator-led brand on national shelves. A drug-capable, precision-dosing factory behind it. Built, branded, and compliance-ready for QVC.
Consumers no longer ask “which cream?” They ask “what do I take, every day, to look, age and feel better?” Gummies and chewables are the fastest-growing format in that shift — and no one yet owns the homeopathic-OTC corner of it.
QVC reaches 250M+ homes and rewards three things above all: a product that demonstrates, a story that travels, and claims that survive review. This line delivers all three.
Articles in the Homeopathic Pharmacopeia of the United States are drugs by statute. That status lets the line carry a Drug Facts panel and make structured support claims a plain supplement legally cannot — with no New Drug Application required.
The homeopathic posture is a differentiator only if it is operated carefully. The line that wins isn’t the one making the boldest claims — it’s the one whose claims survive an FDA letter and an FTC inquiry without a recall. That is the version a retailer like QVC, and a strategic acquirer, can underwrite.
A homeopathic OTC drug lives and dies by its label. Every SKU in the line is built to the same compliance architecture. Below, the requirement on the left and how each pouch satisfies it on the right — with GLOW as the worked example.
Each product pairs two HPUS-monographed actives with a named nutritional-support matrix. Tap any product for its actives, claims architecture, Drug Facts and the backable market-position line.
Each product makes two kinds of promises and keeps them clearly apart — the gentle, traditional ones drawn from its homeopathic actives, and the evidence-backed ones from the nutrients built in around them. That clean separation is exactly what a QVC QA reviewer and an FTC examiner look for.
Each item arrives with a claims matrix of ≤17 prioritized performance claims, each mapped to its substantiation — HPUS materia-medica citations for drug-use claims, peer-reviewed literature for ingredient claims — packaged as PDFs for the QA Spec Card, 6–8 weeks ahead of air. Impermissible language (disease, cure, “clinically proven,” “FDA approved”) is pre-excluded at the source.
The brand is already on national shelves with the margin structure owned manufacturing predicts.
Ulta Beauty · Target · Nordstrom · Sprouts Farmers Market · The Vitamin Shoppe · nationwide CVS (5 of 7 SKUs across 4,400+ doors) — with Amazon expansion underway. The hardest gate in consumer products is already open.
The exact profile being built has repeatedly cleared hundreds of millions to over a billion dollars.
| Comparable | Outcome | Relevance |
|---|---|---|
| Grüns | Unilever, ~$1.2B (2026) | Creator-driven gummy/VMS; ~$300M run-rate by month 24 |
| Rhode | e.l.f. Beauty, ~$1B (2025) | Strategic premium for a creator-led beauty platform |
| Nutrafol | Unilever, up to ~$1B (2022) | Subscription-led wellness with claims discipline |
| Olly | Unilever, ~$200M+ (2019) | Mainstream VMS gummy CPG benchmark |
| Hims & Hers | Public, ~$5.5–6.6B EV | What a vertically integrated consumer-health platform earns |
Comparable transactions and public metrics are as publicly reported and are context for value-creation logic, not forecasts or price targets.
Beyond the pitch — the regulatory and commercial objections this line has to clear, named plainly and answered. An honest bear case is the fastest route to a green light.
Almost everyone in beauty-from-within rents the factory and outsources the gummy. HYEX owns the brand, the manufacturing, the precision-dosing IP and the regulatory architecture — the difference between being valued as one beauty brand and as the platform a category is built on.
The flagship demand engine. Founded 2021 in Toronto, co-founded by Sommer Ray (40M+ combined following, Chief Innovation Officer post-acquisition). A vegan, sugar-free, gelatin-free ingestible-beauty line across skin, hair, hormonal, sexual-wellness, lash & brow and anti-blemish need-states — built on genuine demand, not paid acquisition.
The platform. Healthy Extracts Inc. (OTCQB: HYEX) owns the whole stack — a creator-led brand, an FDA-registered GMP/HACCP facility (Gummy USA, a wholly owned subsidiary) with precision-dosing capability for supplement-to-pharmaceutical drug-product gummies, a reusable regulatory/claims architecture, and a repeatable innovation engine. Acquired Imaraïs in 2026 (~$20M).